Raymond James on Regeneron Pharma (REGN): 'New Survey Indicates 1Q26 Uptick for Eylea HD, More to Come'
April 8, 2026 5:07 AM
Raymond James analyst Chris Raymond reiterated an Outperform rating and $910.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
